See more : Novan, Inc. (NOVN) Income Statement Analysis – Financial Results
Complete financial analysis of Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chengdu Easton Biopharmaceuticals Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (VLRS) Income Statement Analysis – Financial Results
- ENRG Elements Limited (EEL.AX) Income Statement Analysis – Financial Results
- Restaurant Brands International Inc. (0VFA.L) Income Statement Analysis – Financial Results
- Guangdong Guanghua Sci-Tech Co., Ltd. (002741.SZ) Income Statement Analysis – Financial Results
- Sri panwa Hospitality Real Estate Investment Trust (SRIPANWA.BK) Income Statement Analysis – Financial Results
Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS)
About Chengdu Easton Biopharmaceuticals Co., Ltd.
Chengdu Easton Biopharmaceuticals Co., Ltd. engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms in anesthetic/analgesics, cardiovascular, oncology, pediatrics, and other therapeutic fields. It also offers active pharmaceutical ingredients in oncology, cardiovascular, anesthetic/analgesics, anti-inflammatory, gastrointestinal, antiemetic, neurology/psychiatry , and urinary system therapeutic categories. The company was founded in 2009 and is based in Chengdu, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.12B | 1.17B | 1.02B | 921.92M | 947.24M | 768.76M | 476.34M | 338.80M | 240.72M | 208.74M | 162.50M |
| Cost of Revenue | 223.27M | 196.00M | 143.31M | 104.98M | 92.33M | 87.36M | 71.24M | 70.28M | 107.97M | 104.89M | 93.63M |
| Gross Profit | 893.85M | 974.51M | 879.62M | 816.94M | 854.91M | 681.40M | 405.10M | 268.53M | 132.75M | 103.85M | 68.87M |
| Gross Profit Ratio | 80.01% | 83.25% | 85.99% | 88.61% | 90.25% | 88.64% | 85.04% | 79.26% | 55.15% | 49.75% | 42.38% |
| Research & Development | 238.49M | 230.79M | 200.70M | 153.91M | 156.57M | 124.40M | 77.22M | 45.56M | 33.50M | 27.97M | 24.93M |
| General & Administrative | 18.77M | 18.98M | 17.05M | 18.56M | 52.46M | 15.32M | 25.55M | 31.79M | 54.12M | 42.22M | 35.41M |
| Selling & Marketing | 325.67M | 474.14M | 468.10M | 472.05M | 535.26M | 412.05M | 223.57M | 145.37M | 33.48M | 28.65M | 17.46M |
| SG&A | 344.19M | 493.11M | 485.15M | 490.62M | 587.73M | 427.38M | 249.11M | 177.16M | 87.43M | 70.18M | 53.72M |
| Other Expenses | 69.43M | 24.50M | -4.04M | -17.83M | -665.48K | -806.82K | 202.36K | 26.09M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 652.11M | 748.40M | 681.81M | 626.70M | 743.63M | 534.05M | 331.11M | 228.78M | 89.18M | 67.45M | 52.40M |
| Cost & Expenses | 875.38M | 944.41M | 825.12M | 731.68M | 835.96M | 621.41M | 402.35M | 299.05M | 197.15M | 172.34M | 146.02M |
| Interest Income | 14.70M | 12.84M | 4.47M | 3.73M | 1.44M | 2.30M | 1.11M | 291.33K | 346.78K | 2.14M | 683.96K |
| Interest Expense | 3.42M | 2.61M | 364.15K | 724.45K | 171.93K | 132.61K | 92.13K | -9.24K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 74.72M | 59.69M | 33.79M | 33.94M | 27.95M | 25.43M | 23.88M | 21.87M | 19.81M | 12.60M | 8.48M |
| EBITDA | 319.89M | 324.01M | 281.29M | 233.90M | 144.04M | 173.90M | 98.44M | 61.62M | 61.33M | 43.31M | 21.30M |
| EBITDA Ratio | 28.64% | 26.19% | 25.99% | 25.69% | 15.17% | 22.89% | 20.83% | 18.61% | 25.48% | 20.75% | 13.10% |
| Operating Income | 241.74M | 260.63M | 244.15M | 198.80M | 114.73M | 149.14M | 74.27M | 39.42M | 41.53M | 30.71M | 12.81M |
| Operating Income Ratio | 21.64% | 22.27% | 23.87% | 21.56% | 12.11% | 19.40% | 15.59% | 11.63% | 17.25% | 14.71% | 7.88% |
| Total Other Income/Expenses | -241.66K | 1.36M | 111.45M | 80.33M | 1.18M | -806.82K | 202.36K | 26.09M | 2.39M | 3.57M | 2.98M |
| Income Before Tax | 241.50M | 261.99M | 246.92M | 199.05M | 115.91M | 148.33M | 74.47M | 65.51M | 43.92M | 34.27M | 15.79M |
| Income Before Tax Ratio | 21.62% | 22.38% | 24.14% | 21.59% | 12.24% | 19.29% | 15.63% | 19.34% | 18.24% | 16.42% | 9.72% |
| Income Tax Expense | 15.07M | 15.47M | 14.49M | 20.89M | 7.30M | 13.31M | 10.10M | 8.19M | 6.30M | 5.04M | 1.06M |
| Net Income | 226.57M | 246.52M | 232.43M | 178.16M | 108.61M | 135.02M | 64.37M | 57.32M | 37.62M | 29.23M | 14.73M |
| Net Income Ratio | 20.28% | 21.06% | 22.72% | 19.33% | 11.47% | 17.56% | 13.51% | 16.92% | 15.63% | 14.00% | 9.07% |
| EPS | 1.29 | 2.05 | 1.94 | 1.48 | 0.90 | 1.50 | 0.72 | 0.66 | 0.43 | 0.35 | 0.18 |
| EPS Diluted | 1.89 | 2.05 | 1.94 | 1.48 | 0.90 | 1.50 | 0.72 | 0.66 | 0.43 | 0.35 | 0.18 |
| Weighted Avg Shares Out | 176.22M | 120.09M | 120.09M | 120.09M | 120.09M | 90.01M | 89.40M | 86.84M | 87.49M | 83.52M | 81.84M |
| Weighted Avg Shares Out (Dil) | 119.88M | 120.09M | 120.09M | 120.09M | 120.09M | 90.01M | 89.40M | 86.84M | 86.50M | 83.52M | 81.84M |
Source: https://incomestatements.info
Category: Stock Reports